Treatment of HIV-1 infection: Emtricitabin/Tenofovirdisoproxil Amarox is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults (see section 5.1). Emtricitabin/Tenofovirdisoproxil Amarox is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents (see sections 4.2, 4.4 and 5.1). Pre-exposure prophylaxis (PrEP): Emtricitabin/Tenofovirdisoproxil Amarox is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents at high risk (see sections 4.2, 4.4 and 5.1).
Treatment of HIV-1 infection: Emtricitabine/ Tenofovir disoproxil is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults (see section 5.1) Emtricitabine/ Tenofovir disoproxil is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years (see section 5.1). Pre-exposure prophylaxis (PrEP): Emtricitabine/ Tenofovir disoproxil is indicated in combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk (see sections 4.4 and 5.1).
The primary objective of this study is to evaluate the efficacy of fixed-dose combination (FDC) of bictegravir/emtricitabine/ tenofovir alafenamide (B/F/TAF) versus dolutegravir (DTG) + emtricitabine/tenofovir disoproxil fumarate...
The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...
Ictastan is a fixed dose combination of emtricitabine and tenofovir disoproxil succinate. It is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults aged 18 years and over. The demonstration of the benefit of the combination emtricitabine and tenofovir disoproxil in antiretroviral therapy is based solely on studies performed in treatment-naïve patients (see section 5.1).
Gilead Sciences, Inc.announced that the company�s Marketing Authorization Application (MAA) for two doses of an investigational fixed-dose combination of emtricitabine...